There is nothing wrong with the science, but it will take time to develop and refine.
However, as we all know immunotherapies is an extremely expensive area to be involved in. Admedus will not burden the core business with this cost into the future, Wayne is to smart for that. He has made it abundantly clear in his last three online presentations that they are two different businesses in essence.
He will restructure the company to separate them. I would expect we will know the details soon.
All IMO
Tissue Engineering v. Immunotherapy, page-7
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
0.000(0.00%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 73 | $17.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.80 | 9 | 1 |
View Market Depth
| Last trade - 13.51pm 22/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |
Day chart unavailable